| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Staphylococcus aureus endocarditis: a consequence of medical progress.
|
JAMA
|
2005
|
7.41
|
|
2
|
Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children.
|
JAMA
|
2004
|
2.90
|
|
3
|
Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations.
|
PLoS Med
|
2007
|
2.58
|
|
4
|
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
|
Drugs
|
2013
|
2.33
|
|
5
|
Comparative review of the carbapenems.
|
Drugs
|
2007
|
2.06
|
|
6
|
Linezolid: a review of safety and tolerability.
|
J Infect
|
2009
|
1.95
|
|
7
|
Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings.
|
Clin Infect Dis
|
2004
|
1.95
|
|
8
|
The changing face of Klebsiella pneumoniae infections in the community.
|
Int J Antimicrob Agents
|
2007
|
1.73
|
|
9
|
Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
|
Drugs
|
2009
|
1.41
|
|
10
|
Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit.
|
Emerg Infect Dis
|
2005
|
1.32
|
|
11
|
Pyogenic liver abscess caused by hypermucoviscous Klebsiella pneumoniae.
|
Scand J Infect Dis
|
2007
|
1.29
|
|
12
|
New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
|
Drugs
|
2010
|
1.29
|
|
13
|
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
|
Drugs
|
2014
|
1.27
|
|
14
|
The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS).
|
Am Heart J
|
2007
|
1.26
|
|
15
|
The pneumococcal pilus predicts the absence of Staphylococcus aureus co-colonization in pneumococcal carriers.
|
Clin Infect Dis
|
2009
|
1.23
|
|
16
|
Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.
|
Expert Rev Anti Infect Ther
|
2007
|
1.23
|
|
17
|
Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.
|
Emerg Infect Dis
|
2014
|
1.17
|
|
18
|
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
|
Respir Res
|
2010
|
1.14
|
|
19
|
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
|
Expert Rev Anti Infect Ther
|
2012
|
1.11
|
|
20
|
Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus.
|
Clin Infect Dis
|
2009
|
1.09
|
|
21
|
Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals.
|
PLoS One
|
2013
|
1.05
|
|
22
|
Comparison of community-acquired methicillin-resistant Staphylococcus aureus bacteremia to other staphylococcal species in a neonatal intensive care unit.
|
Eur J Pediatr
|
2006
|
1.05
|
|
23
|
Anti-infective research and development--problems, challenges, and solutions.
|
Lancet Infect Dis
|
2007
|
1.05
|
|
24
|
Chemokine receptor 5 △32 allele in patients with severe pandemic (H1N1) 2009.
|
Emerg Infect Dis
|
2010
|
1.03
|
|
25
|
Influenza epidemiology--past, present, and future.
|
Crit Care Med
|
2010
|
1.02
|
|
26
|
Parental Staphylococcus aureus carriage is associated with staphylococcal carriage in young children.
|
Pediatr Infect Dis J
|
2009
|
0.99
|
|
27
|
Tigecycline: a novel glycylcycline antibiotic.
|
Expert Rev Anti Infect Ther
|
2006
|
0.99
|
|
28
|
Faropenem: review of a new oral penem.
|
Expert Rev Anti Infect Ther
|
2007
|
0.98
|
|
29
|
Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance.
|
J Antimicrob Chemother
|
2004
|
0.97
|
|
30
|
Does pneumococcal conjugate vaccine influence Staphylococcus aureus carriage in children?
|
Clin Infect Dis
|
2008
|
0.96
|
|
31
|
Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation.
|
BMC Public Health
|
2014
|
0.96
|
|
32
|
Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock.
|
Int J Antimicrob Agents
|
2013
|
0.96
|
|
33
|
Staphylococcus aureus bacteremia, risk factors, complications, and management.
|
Crit Care Clin
|
2013
|
0.95
|
|
34
|
In vitro bactericidal activity of Streptococcus pneumoniae and bactericidal susceptibility of Staphylococcus aureus strains isolated from cocolonized versus noncocolonized children.
|
J Clin Microbiol
|
2007
|
0.95
|
|
35
|
Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
|
Drugs
|
2015
|
0.94
|
|
36
|
Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients.
|
J Antimicrob Chemother
|
2002
|
0.93
|
|
37
|
Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
|
Crit Care
|
2005
|
0.92
|
|
38
|
An outbreak of Phialemonium infective endocarditis linked to intracavernous penile injections for the treatment of impotence.
|
Clin Infect Dis
|
2005
|
0.92
|
|
39
|
Adverse reactions to β-lactam antimicrobials.
|
Expert Opin Drug Saf
|
2012
|
0.92
|
|
40
|
Septic arthritis due to Roseomonas gilardii in an immunocompetent adolescent.
|
J Med Microbiol
|
2009
|
0.91
|
|
41
|
Pathophysiology of infective endocarditis.
|
Curr Infect Dis Rep
|
2013
|
0.91
|
|
42
|
A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.
|
Treat Respir Med
|
2006
|
0.91
|
|
43
|
Role of agr (RNAIII) in Staphylococcus aureus adherence to fibrinogen, fibronectin, platelets and endothelial cells under static and flow conditions.
|
J Med Microbiol
|
2002
|
0.90
|
|
44
|
Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population.
|
J Am Med Dir Assoc
|
2005
|
0.90
|
|
45
|
Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.
|
Hum Vaccin Immunother
|
2013
|
0.89
|
|
46
|
Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
|
Expert Rev Anti Infect Ther
|
2008
|
0.88
|
|
47
|
Novel agents for resistant Gram-positive infections--a review.
|
Int J Infect Dis
|
2002
|
0.88
|
|
48
|
Reduction in antibiotic use following a cluster randomized controlled multifaceted intervention: the Israeli judicious antibiotic prescription study.
|
Clin Infect Dis
|
2011
|
0.87
|
|
49
|
Overview of seizure-inducing potential of doripenem.
|
Drug Saf
|
2009
|
0.87
|
|
50
|
Is in vitro antibiotic combination more effective than single-drug therapy against anthrax?
|
Antimicrob Agents Chemother
|
2005
|
0.85
|
|
51
|
Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia.
|
Int J Antimicrob Agents
|
2013
|
0.85
|
|
52
|
Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan.
|
Can J Infect Dis Med Microbiol
|
2008
|
0.84
|
|
53
|
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.
|
Antimicrob Agents Chemother
|
2014
|
0.83
|
|
54
|
Infective endocarditis in the intensive care unit.
|
Crit Care Clin
|
2013
|
0.83
|
|
55
|
Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies.
|
BMC Infect Dis
|
2014
|
0.82
|
|
56
|
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
|
Am J Clin Dermatol
|
2008
|
0.81
|
|
57
|
Multidrug-resistant North American pulsotype 2 Clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006-2007.
|
J Med Microbiol
|
2012
|
0.80
|
|
58
|
Endogenous endophthalmitis caused by hypermucoviscous Klebsiella pneumoniae: an emerging disease in Southeast Asia and beyond.
|
Curr Infect Dis Rep
|
2008
|
0.80
|
|
59
|
Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).
|
J Antimicrob Chemother
|
2013
|
0.80
|
|
60
|
Appropriate use of antibiotics for respiratory infections: review of recent statements and position papers.
|
Curr Opin Infect Dis
|
2002
|
0.80
|
|
61
|
Changing parents' opinions regarding antibiotic use in primary care.
|
Eur J Pediatr
|
2010
|
0.79
|
|
62
|
Independent risk factors for carriage of penicillin-non-susceptible Streptococcus pneumoniae.
|
Scand J Infect Dis
|
2003
|
0.78
|
|
63
|
Experimental pneumococcal pleural empyema model: the effect of moxifloxacin.
|
J Antimicrob Chemother
|
2003
|
0.78
|
|
64
|
Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals.
|
J Antimicrob Chemother
|
2013
|
0.77
|
|
65
|
Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
|
Expert Opin Drug Metab Toxicol
|
2013
|
0.77
|
|
66
|
Are drug clinical trials broadly applicable? The case of staphylococcal bacteraemia.
|
Int J Antimicrob Agents
|
2009
|
0.77
|
|
67
|
Genetic polymorphisms and drug susceptibility in four isolates of Leishmania tropica obtained from Canadian soldiers returning from Afghanistan.
|
PLoS Negl Trop Dis
|
2012
|
0.77
|
|
68
|
Fungal Endocarditis.
|
Curr Infect Dis Rep
|
2004
|
0.77
|
|
69
|
Excision of nucleoside analogs from DNA by p53 protein, a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
|
Antimicrob Agents Chemother
|
2005
|
0.76
|
|
70
|
Diabetes mellitus and pyogenic liver abscess: risk and prognosis.
|
Clin Infect Dis
|
2007
|
0.76
|
|
71
|
HAP/VAP: Simpler may be better.
|
Can J Infect Dis Med Microbiol
|
2008
|
0.75
|
|
72
|
Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
|
J Antimicrob Chemother
|
2003
|
0.75
|
|
73
|
Targeting the chemokine receptor CCR5: good for HIV, what about other viruses?
|
J Infect Dis
|
2011
|
0.75
|
|
74
|
Resistant organisms and otitis media.
|
Pediatr Infect Dis J
|
2005
|
0.75
|